ScripRoche affiliate Genentech revealed on July 18 that the US Food and Drug Administration denied a supplemental approval for its bispecific antibody Columvi (glofitamab-gxbm) in relapsed/refractory diffu
Pink SheetUpcoming federal spending reductions and resulting coverage losses in Medicaid could have a significant impact on patient access to drugs for HIV, cystic fibrosis and mental health, as well as treatme
ScripAt least officially, Bristol Myers Squibb and Pfizer’s are selling the anticlotting drug Eliquis (apixaban) directly to consumers to lower costs for patients, especially those who are uninsured, under
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Debiopharm Gets Global Rights To Repare